Hexarelin vs Liraglutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Hexarelin
Hexarelin is a potent synthetic hexapeptide growth hormone secretagogue. It provides the strongest GH release among GHRPs but is associated with rapid desensitization of receptors.
Full details →Liraglutide
Liraglutide is a GLP-1 receptor agonist FDA-approved as Victoza for type 2 diabetes and Saxenda for chronic weight management. It was one of the first daily GLP-1 agonists and paved the way for newer weekly options like semaglutide.
Full details →Side-by-Side Comparison
| Aspect | Hexarelin | Liraglutide |
|---|---|---|
| Mechanism | Acts as a ghrelin mimetic with high potency at the GHS receptor. Provides powerful GH release but receptor desensitization occurs faster than with other GHRPs, requiring cycling. | Binds to and activates GLP-1 receptors, stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system effects. |
| Typical Dosage | Typical dosing: 100-200mcg administered 2-3 times daily for 4-6 weeks, followed by an equal off period to allow receptor resensitization. | Saxenda (weight loss): Start 0.6mg daily, increase weekly by 0.6mg to maintenance dose of 3mg daily. Victoza (diabetes): 0.6mg to 1.8mg daily. |
| Administration | Subcutaneous injection. Cycling is essential to maintain effectiveness. Often used in short bursts rather than continuous protocols. | Subcutaneous injection once daily at any time, independent of meals. Rotate injection sites. Can be used with oral diabetes medications. |
| Side Effects | Water retention, cortisol and prolactin increase, hunger (moderate), tingling, and potential blood pressure effects. | Nausea, vomiting, diarrhea, constipation, headache, decreased appetite. GI effects typically diminish over time with continued use. |
| Best For |